Real Cost of Pharma Serialization at a Russian ZTK in 2026 — GDP Requirements, MDLP Integration and Break-Even
The fee for a single marking code in the «Chestny Znak» system is 50 kopecks excluding VAT. This is a fixed rate, identical for everyone. However, when an importer transfers a batch of medicines to a customs warehouse for code application, the final invoice per individual pack can reach 15–40 rubles. This price gap is neither accidental nor arbitrary: it is driven by a specific cost structure that is worth understanding in order to budget effectively, choose an operational model, and avoid being caught off guard by the numbers.
For a pharmaceutical importer, choosing between labeling at a foreign manufacturing site and labeling in Russia at a customs warehouse — Zone of Customs Control, or ZTK — is one of the most practical questions in operational planning. It directly affects batch cost, time to market, and the risk of sales blockages.
How Labeling Worked Until 2023
The Medicine Circulation Monitoring System (MDLP) became mandatory on July 1, 2020. Decree of the Government of the Russian Federation No. 1556 dated December 14, 2018 (hereinafter — Decree No. 1556) established the foundational rules: means of identification are applied to secondary (consumer) packaging, or to primary packaging if secondary packaging is absent.
Clause 4 of Decree No. 1556 explicitly secured two pathways for applying DataMatrix codes to imported drugs. The first pathway involves labeling at a foreign manufacturing site upon completion of the packaging stage. The second pathway consists of applying a label with the code within Russia at a customs warehouse, provided its address is listed in the pharmaceutical activity license of the organization engaged in wholesale trade of medicines.
In 2020–2022, the majority of large foreign manufacturers opted for the first scenario. Factories in Germany, France, India, and China integrated their equipment with the Russian system. Labeling at a ZTK was largely perceived as a temporary fallback for latecomers.
In 2023–2024, the picture changed. New suppliers from countries that had never interacted with the MDLP demanded a quick-start tool without lengthy manufacturing integration. Drugs previously sourced through established supply chains began arriving from alternative manufacturers. Demand for labeling services at ZTKs surged, and along with it, the regulator’s requirements for the warehouses themselves grew significantly stricter.
What Changed in 2024–2025
The Legal Basis for Labeling at a ZTK
The underlying mechanism has remained the same. The importer places the goods under the customs warehouse procedure. While the goods are located within the zone of customs control, an authorized organization applies the marking code to the packaging.
This requirement is anchored in Clause 4 of Decree No. 1556: when importing from non-EAEU countries, it is permissible to apply a label with the code by printing it onto a physical medium and subsequently affixing it to the package. The medium must be non-detachable from the packaging without causing damage. Following labeling, the holder or owner of the registration certificate must transmit data about the operation to the MDLP within 5 business days of the completion date of labeling (subclause «z» of clause 3, clause 36 of Decree No. 1556 as currently amended).
The means of identification in the MDLP is a two-dimensional DataMatrix barcode with a quality grade of C or higher in accordance with GOST R ISO/IEC 16022-2008 and GOST R ISO/IEC 15415-2012. The identification code for transport packaging is formed according to GOST ISO/IEC 15417-2013 (Code 128) and contains 18 characters.
Warehouse Requirements Have Intensified
Not every customs warehouse is permitted to handle medicines. Two conditions must be met: a pharmaceutical license for wholesale trade and compliance with the Good Distribution Practice (GDP) Rules approved by Decision of the Council of the Eurasian Economic Commission No. 80 dated November 3, 2016 (hereinafter — Decision No. 80).
Order of the Ministry of Health of Russia No. 260n dated April 29, 2025, «On Approval of the Rules for Storage of Medicinal Products for Medical Use» (which entered into force on September 1, 2025) specified concrete requirements for the premises of wholesale trade organizations: a minimum area of 150 sq. m., division into functional zones (receiving, main storage, quarantine, storage of non-compliant medicines, dispatch), and climate control systems equipped with calibrated temperature and humidity measuring instruments. The requirements for wholesalers’ premises directly cross-reference subsection 3 of section III of the GDP Rules (Decision No. 80).
The GDP Rules add a substantial organizational burden: a designated Responsible Person with a pharmaceutical education, a quality system with documented Standard Operating Procedures (SOPs), and regular internal audits. The Responsible Person must be accessible at all times.
For cold-chain (thermolabile) preparations — such as insulin, vaccines, or biologics — warehouses additionally require cold chambers operating in the +2…+8°C range, validated temperature monitoring systems, and documented corrective action protocols for temperature deviations.
According to market operator estimates, out of more than 200 customs warehouses in Russia, no more than 20 possess both a pharmaceutical license and GDP compliance. This limited supply set against growing demand is a direct driver of pricing.
The Permissive Regime from 2025 Onward
Starting March 1, 2025, Article 57 of Federal Law No. 61-FZ dated April 12, 2010, «On the Circulation of Medicines» (as amended by Federal Law No. 292-FZ dated August 8, 2024) prohibits the sale of medicines for which information regarding the application of identification means and/or information on entry into civilian circulation is absent from the MDLP.
The grounds for prohibiting sales are codified in Part 2 of Article 57 of Law No. 61-FZ: absence of code application or entry-into-circulation records in the MDLP; blocking of data entry into the system; suspension of the drug’s use by decision of the Ministry of Health; termination of civilian circulation; expiration of shelf life; and failure to comply with the requirements of Part 5 of Article 67 of Law No. 61-FZ.
The procedure for applying these bans is established by the Government of the Russian Federation (Part 4 of Article 57 of Law No. 61-FZ). For an importer, this translates into heightened requirements for marking quality: a single error in a code blocks sales throughout the entire chain. Distributors will refuse to accept the goods; pharmacies will be unable to sell them.
The list of reasons for blocking is also defined by Decree No. 1556 (Appendix No. 7). Among them: a discrepancy between the Global Trade Item Number (GTIN) in the MDLP and the state registry of medicines, the absence of a valid license held by the circulation subject, or a block initiated by Roszdravnadzor.
Breakdown of Labeling Costs at a ZTK
The real cost of labeling is built from four layers of expenses, each of which might seem negligible on its own, but combined they yield those same 15–40 rubles per package.
Direct Costs for Codes and Application
The emission of a marking code in the «Chestny Znak» system costs 50 kopecks without VAT (60 kopecks with VAT). For a batch of 100,000 packs, this amounts to 60,000 rubles. A noticeable line item, but far from the primary driver.
The physical application service includes retrieving the marking code via an Emission Registration Device (URE / УРЭ), printing the label on an industrial-grade printer, affixing the label to the package, and verifying the code using a 2D scanner. Code quality requirements are strict: a Grade C minimum per GOST R ISO/IEC 15415-2012. Every single unit undergoes verification.
Application at a ZTK is almost always a manual operation. Automated lines cost tens of millions of rubles and only become economically viable at volumes of several million packages per year. The manual labor of a qualified worker inside a pharmaceutically licensed facility is expensive.
Aggregation — generating a transport packaging identification code and uploading data to the MDLP regarding which consumer packs are inside which box — is tariffed as a distinct operation. Under Clause 40 of Decree No. 1556, the transport packaging identification code must be applied and registered by the circulation subject. It may either be bundled into the application price or billed separately.
Storage during the labeling period is calculated per pallet position or by occupied floor space for every 24-hour period. With large batches and processing backlogs, the storage invoice accumulates rapidly.
Infrastructure Expenses for the Importer
To interact with the MDLP system, an enhanced qualified electronic signature (EQES / UKEP) belonging to the head of the organization is required. The Federal Tax Service (FNS) issues it free of charge, but secure hardware tokens and cryptographic software must be purchased separately.
To obtain GTIN codes, membership in the GS1 Russia association is required. The annual fee depends on the legal structure and financial turnover of the organization.
Data transfer to the MDLP is handled either manually via the user dashboard or automatically through ERP system integration (1C or equivalents). Automation demands upfront investment but reduces the operational risk of errors.
Electronic Data Interchange (EDI) with counterparties is also a mandatory expense. Without EDI, confirming transactions in the MDLP within the legally mandated timeframes under Clause 37 of Decree No. 1556 is not possible.
The Risk Component
This is the most «invisible» component of the price. An aggregation error — a mismatch between the data in the MDLP and the actual physical contents of a box — can serve as grounds for a customs authority to refuse the release of a customs declaration. The goods get stuck at the warehouse, and storage fees continue to accumulate.
A damaged or unreadable code necessitates relabeling. This involves the full recurrent cost of application plus the labor costs of removing the old labels.
Data errors — an incorrect GTIN or a mismatched lot number — lead to system-level blocks in the MDLP according to subclauses 6 and 9 of Appendix No. 7 to Decree No. 1556. Unblocking takes time, during which sales remain entirely frozen.
Selling or storing medicines without proper marking triggers liability under Article 15.12 of the Code of Administrative Offenses (KoAP RF) — applying counterfeit excise marks or identification means to goods, or storing such goods — and under Article 6.33 of the KoAP RF (circulation of falsified, counterfeit, or substandard medicines). Skimping on processing quality with a verified operator routinely results in losses far exceeding any short-term savings.
Comparison of the Three Labeling Models
| Parameter | At the Manufacturing Plant | At a ZTK in Russia | In Foreign Hubs |
|---|---|---|---|
| Cost per package | Minimal | 15–40 ₽ | Depends on the country |
| Process control | Managed by manufacturer | Full control, in Russia | Managed by external operator |
| Launch timeline | 6–12 months of integration | Immediate | 2–4 months |
| Error correction | Only after import | Prior to entry into circulation | Only after import |
| Risk when changing suppliers | High | Low | Medium |
| Suitable for small batches | No | Yes | No |
When labeling at the manufacturing plant, the DataMatrix code is printed directly during the packaging process and is integrated into the production line. The unit cost is minimal. However, integrating a foreign factory with the MDLP takes 6 to 12 months and requires substantial investment. If the supplier changes, the process must start over.
Labeling at a ZTK costs more per unit. On the other hand, the process is entirely controlled by the Russian entity, errors are caught and corrected before the drugs enter civilian circulation, and the foreign manufacturer does not need to undergo any technical integration with the Russian system.
Labeling in foreign hubs (China, Turkey, CIS countries) attracts importers due to a potentially lower price. However, any errors in the codes will only be detected after the batch arrives in Russia, at which stage correcting them is already expensive. Currency fluctuations and logistical delays introduce additional layers of risk.
The Economies of Scale
The cost of labeling at a ZTK depends on the volume of the batch.
For small batches (1,000 to 10,000 packs), infrastructure expenses — GS1 membership, electronic signature, potential ERP integration — are spread across a small number of units. The unit cost peaks here.
For medium batches (10,000 to 100,000 packs), the unit cost begins to drop. Fixed costs are amortized over a larger volume, and warehouse operators offer more competitive tariffs.
For large batches (over 100,000 packs), the unit cost reaches its minimum. However, it is precisely at this volume that the absolute financial difference between factory labeling and ZTK labeling becomes most visible on the balance sheet.
For most companies, the break-even point — the volume at which capital investment into foreign factory integration pays off compared to recurring annual expenses at a ZTK — lies within the range of 200,000 to 500,000 packages per year. Below this threshold, labeling at a ZTK remains economically rational despite the higher unit cost.
When Labeling at a ZTK Is Fully Justified
Four specific scenarios make a ZTK the preferred operational choice, even with the higher per-pack cost.
A new supplier without MDLP integration. If a foreign manufacturer has never worked with Russian regulatory requirements before, setting up their production lines for the MDLP takes 6 to 12 months. A ZTK allows the importer to bring the drug to market immediately while integration runs in parallel.
Small and irregular batches. For batches of a few thousand packs of low-volume or orphan drugs, investing in factory production line integration is financially unviable. Labeling at a ZTK is the only logical framework.
Unstable logistics. When a manufacturer is located in a jurisdiction subject to sanctions or high logistical risk, labeling in Russia reduces dependence on the uninterrupted operation of foreign supply chains. Different manufacturers and different shipping routes can all feed into a single labeling point in Russia.
Correcting errors on imported goods. If a batch has already arrived in Russia and errors are discovered within the codes — an incorrect GTIN or a lot number mismatch — the only legal way to rework the inventory is relabeling at a customs warehouse holding the appropriate pharmaceutical license.
What to Do
Audit your current model. Gather actual cost data for labeling over the past 12 months. Separate expenses into fixed (GS1 membership, software integration, EDI licenses) and variable (application fee per unit, storage, aggregation). Calculate the exact share of labeling costs in the cost of goods sold for each SKU in your portfolio.
Calculate the break-even point for each SKU. Take your projected annual import volumes. Calculate the volume at which the cost of integrating a foreign manufacturer (one-time setup plus annual maintenance) offsets the premium paid for application at a ZTK. Factor in not just the direct costs, but also the cost of the 6–12 months that factory integration will require.
Check manufacturer readiness. Clarify with your foreign partner whether they are already working with the «Chestny Znak» system for other clients. If they are, integration for your specific drug might take 1–2 months instead of 6–12. This significantly shifts the break-even calculation.
Select a ZTK with a valid pharmaceutical license. Verify that the warehouse address is explicitly listed in a valid pharmaceutical activity license. Confirm that they have the correct temperature-controlled zones for your specific products. Request data on their throughput capacity and standard batch processing turnaround times.
Minimize warehouse dwell time. Pre-order and emit marking codes in the system ahead of time, and transfer batch data to the operator before the cargo physically arrives. Coordinate the work schedule and file the customs declaration for release immediately upon completion of labeling. Every extra day in the warehouse translates into additional storage fees.
A properly configured labeling workflow at a ZTK generally accounts for 1–3% of the total batch value for medium-sized volumes. This is a highly predictable operational expense, offset by rapid time-to-market and full independence from foreign IT infrastructure.
Regulatory Framework:
1. Order of the Ministry of Health of Russia No. 260n dated 29.04.2025 «On Approval of the Rules for Storage of Medicinal Products for Medical Use» (entered into force on 01.09.2025)
2. Decree of the Government of the Russian Federation No. 1556 dated 14.12.2018 (as amended on 29.09.2025) «On Approval of the Regulation on the System for Monitoring the Movement of Medicinal Products for Medical Use»
3. Federal Law No. 61-FZ dated 12.04.2010 «On the Circulation of Medicines» (as amended on 08.08.2024), Article 57
4. Decision of the Council of the Eurasian Economic Commission No. 80 dated 03.11.2016 «On Approval of the Rules of Good Distribution Practice within the Eurasian Economic Union»